← Stocks 한국어 ↗

Samsung C&T (028260) 🔎 In-depth

KOSPI · Price as of 2026-11-12 · Metrics 2026-11-13 · In-depth research 2026-11-07

Compiled and reviewed by Bing Bing · Methodology · AI Disclosure · Report an error

Samsung C&T is an operating holding company: it runs its own businesses, including construction of chip plants and apartments, commodity trading, and fashion, leisure and food services, while holding core group stakes such as Samsung Electronics, Samsung Biologics and Samsung Life Insurance, and about 60% of its operating profit comes from its biotech subsidiaries. In Q3 2026, revenue rose 18.3% to ₩12.008 trillion and operating profit rose 15.0% to ₩1.1428 trillion, led by high-tech construction projects, and the company raised its new-order guidance for the year from ₩23.5 trillion to ₩30.1 trillion. On the positive side, its market cap is less than half the market value of its listed stakes (about ₩111.4 trillion as of November 3), and a special dividend from Samsung Electronics brings this year's forward P/E down to 13.05x. On the cautious side, its asset value moves sharply with Samsung Electronics' share price, and if dividends at this level do not continue, next year's multiple could rise again.

This page organises public market and filing data for information purposes. It is not a recommendation to buy or sell, nor investment advice. Metrics labelled “forward” are our own unverified estimates. Please verify with the original DART filings and decide at your own responsibility.

Data sources

Prices & market cap from the FSC securities price API (data.go.kr) · filings & financials from OpenDART (FSS) · listings from the Korea Exchange.

Prices as of 2026-11-12. Methodology is public on the methodology page.

₩284,500 +0.53%
Market cap $34.6B

30-second brief

Earnings trend
revenue and profit declined.
Financials
debt levels look manageable.
Data as of
prices as of 2026-11-12, financials as of Q1 2026.

Auto-extracted from the computed values.

What do the SourceComputedEstimateReading tags mean?

Source filings and exchange data · Computed calculated from public data · Estimate our own unverified projection · Reading drafted automatically, then rule-checked. See AI & Automation.

Core valuation metric

Discount to NAV55.4% discount

This stock's effective sub-sector is “Holding Companies”, a type typically read first through discount to NAV.

A holding company is less a maker of products than a vessel that holds stakes in several subsidiaries. So rather than an earnings multiple, the first lens is the discount to NAV — the market value against the summed worth of everything it owns.

Forward P/E (current-year estimate)12.78x

Price against assets alone says little about where the cycle stands. Reading it together with price against this year's expected earnings shows how far profits have recovered.

This note explains how each sector is typically valued and is educational context only, not investment advice.

At-a-glance assessment financial health · growth · profitability · valuation

Financial healthStable
  • Debt ratio, current ratio and interest burden all look healthy.
GrowthDeclining
  • Revenue fell 3.2% year over year (3-year trend: mixed).
  • Most recent quarter (Q1 2026) revenue was 7.5% higher than a year earlier.
ProfitabilityModerate
  • ROE is 4.2% (controlling-interest basis). It is above the sector average.
  • Operating margin is 7.9%.
ValuationUndervalued
  • Valued against the net asset value (NAV) of its listed holdings rather than a consolidated P/E — see the in-depth valuation for the detailed basis.

Ownership & governance As of 2025-12-31

Largest shareholder Lee Jae-yong 19.76% (individual)

Controlling bloc incl. related parties 36.01%

With the controlling bloc holding 36%, the ownership structure is stable.

Net asset value (NAV) assessment 55% discount to NAV

💡 How to read a holding company · A holding company owns stakes in several subsidiaries. Its P/E swings with equity-method gains and losses on those stakes, so read it only as a rough guide. P/B is more meaningful because subsidiary stakes sit in equity, but book value carries them at low historical cost (so P/B looks higher than reality). The most accurate view is the price against the market value of those stakes (NAV) ↓

Valued against the net asset value (NAV) of its listed holdings rather than a consolidated P/E — see the in-depth valuation for the detailed basis.

Listed subsidiaries ownership

Samsung Biologics43.06%
Samsung Life Insurance19.34%
Samsung SDS17.08%
Samsung E&A6.97%
Samsung Electronics5.01%
Samsung Heavy Industries0.11%

🔎 In-depth analysis Reading

🏢Business

Samsung C&T has two characters at once. First, it is an operating company. The construction division builds chip plants (high-tech), apartments, and power plants and transmission grids overseas. The trading division trades commodities such as steel, fertilizer, chemicals and metals on global markets and develops solar power plants. The fashion division runs apparel brands such as Beanpole, and the leisure division operates Everland as well as golf courses and landscaping. The food division is handled by wholly owned subsidiary Samsung Welstory, which provides institutional catering and food distribution. The biotech division consists of consolidated subsidiaries Samsung Biologics and Samsung Epis Holdings. Samsung Biologics develops and manufactures drugs on behalf of other pharmaceutical companies (contract development and manufacturing), and Samsung Epis Holdings, through its subsidiary, develops and markets biosimilars (copies of biologic drugs whose patents have expired). Revenue and profit are weighted differently. Of Q3 2026 revenue of ₩12.008 trillion, construction contributed ₩4.465 trillion and trading ₩4.2 trillion, more than 70% combined. But of Q1-Q3 operating profit of ₩2.8949 trillion, ₩1.731 trillion (59.8%) came from biotech. Construction contributed ₩590.0 billion, trading ₩351.0 billion, food ₩125.0 billion and fashion ₩111.0 billion, while leisure posted a loss of ₩13.0 billion. Q3 operating margins were 38.3% in biotech and 2.4% in trading, so the profit kept from the same amount of revenue differs greatly. Second, it sits at the top of the Samsung Group's governance structure and acts as a holding company with stakes in core affiliates. As of end-June, its listed affiliate holdings were 298,818,100 Samsung Electronics common shares (about 5.1% of common shares), 43.06% of Samsung Biologics, 43.06% of Samsung Epis Holdings, 19.34% of Samsung Life Insurance, 17.08% of Samsung SDS and 6.97% of Samsung E&A. At November 3 closing prices, the market value of these stakes is about ₩111.4275 trillion, of which Samsung Electronics accounts for ₩65.5906 trillion, or about 60%. Each stake is accounted for differently, so earnings must be read differently too. Samsung Biologics and Samsung Epis Holdings are consolidated subsidiaries, so their revenue and operating profit are added in full. However, about 57% of their net profit belongs to outside shareholders (non-controlling interests) and is excluded from net profit attributable to Samsung C&T shareholders. The stakes in Samsung Electronics, Samsung Life Insurance, Samsung SDS and Samsung E&A are financial assets measured at market prices. Their earnings enter the income statement only as dividends, and share price changes are reflected only in equity, not in profit. Dividends received in H1 2026 were about ₩280.3 billion from Samsung Electronics and about ₩205.0 billion from Samsung Life Insurance.

📈Price & chart

The latest close is ₩284,500 and the market capitalization is ₩46.1 trillion. The price sits below its 20-day moving average (₩294,050) and below its 60-day moving average (₩335,558). It is under both its short- and medium-term moving averages, so the trend looks subdued. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 41.3, a neutral level. The one-month change is -2.4%, the three-month change is -15.3%, and the position relative to the 52-week high is -46.8%. Relative strength versus the KOSPI is 41 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 41% of all stocks. Over the past three months it lagged the index by 2.5%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.

📊Key metrics

The first metric to look at for this company is the discount to NAV (how far market cap sits below the market value of the assets it holds). Most of its assets are affiliate stakes with market prices, but accounting profit does not properly capture that value. Recalculated with November 3 closing prices and end-June share counts, the market value of its listed stakes is ₩111.4275 trillion: Samsung Electronics ₩65.5906 trillion, Samsung Biologics ₩28.9418 trillion, Samsung Life Insurance ₩10.1169 trillion, Samsung Epis Holdings ₩3.2732 trillion, Samsung SDS ₩2.663 trillion and Samsung E&A ₩842.0 billion. With a market cap of ₩46.1 trillion, the stock trades 55.0% below the value of its listed stakes. Adding end-September net cash of ₩4.071 trillion widens the gap to 56.5%. Even after deducting the tax that would apply to valuation gains if the stakes were sold (assuming a 27.5% tax rate), it is about 45.7% lower. The discount to NAV on the screen card (54%) is smaller because it leaves out the Samsung Epis Holdings stake and uses an older Samsung Electronics ownership ratio, understating listed stakes by about ₩4.6 trillion. Compared with other holding companies, the gap is wide. The site's figures, calculated the same way at November 3 closing prices, are 38.2% for SK, 31.6% for HD Hyundai, 19.0% for LG and 72.5% for Hanwha; excluding Hanwha, Samsung C&T's gap is the widest. Subtracting net cash and the market value of listed stakes from market cap gives -₩65.3076 trillion. In effect, the value of the core construction, trading, fashion, leisure and food businesses and unlisted stakes such as Samsung Welstory is not reflected in the share price. Earnings multiples need to be put on a consistent time basis. The 19.31x P/E (share price as a multiple of a year's earnings) on screen is based on full-year 2025 earnings. Recalculated with attributable net profit for the last four quarters of ₩2.7849 trillion, it is 18.0x, and the forward P/E based on this year's expected earnings is 13.05x. Comparable holding companies trade at P/Es on confirmed results of 22.96x for SK, 19.81x for LG, 17.7x for Hanwha and 11.54x for HD Hyundai, so Samsung C&T's multiple for this year is at the lower end of this range. The holding company sector median P/E is around 7.4x, but many holding companies have one-off gains mixed in, so it is used only as a reference. The same goes for P/B (share price as a multiple of book equity). The 0.76x P/B on screen is based on end-March equity; as of September 30, the P/B is 0.74x (equity attributable to owners of ₩88.147 trillion, book value per share of about ₩543,555). On end-September equity, it is lower than SK (1.24x) and HD Hyundai (1.02x) and higher than LG (0.48x) and Hanwha (0.40x). Equity attributable to owners fell by ₩17.406 trillion, from ₩105.553 trillion at end-June to ₩88.147 trillion at end-September, not because profits fell but because the valuation of its holdings, including Samsung Electronics, declined. Because equity includes the valuation of these stakes, this company's P/B moves sharply every quarter with affiliate share prices. ROE (how much the company earns on its equity in a year) also looks low at 3.2% on a last-four-quarters basis, but that largely reflects an equity denominator inflated by valuation gains; on this year's expected earnings it is about 4.1%. Financial strength is solid. At end-September, cash and equivalents were ₩6.848 trillion and total borrowings ₩2.777 trillion, leaving ₩4.071 trillion more cash than debt, a net cash position. The debt ratio (liabilities relative to equity) was 46% as of September 30. Borrowing dependence (borrowings as a share of total assets) was 2.0%, and the current ratio (assets convertible to cash within a year versus liabilities due within a year) was 149%. Enterprise value (EV) metrics can also be updated with the latest figures. EV is market cap plus net debt (debt minus cash), the cost of taking over the whole company. Reflecting end-September net cash, EV is about ₩46.1199 trillion. EV/EBIT (enterprise value as a multiple of operating profit) is 12.4x on the last four quarters and 11.7x on this year's expected operating profit, and EV/Sales (a multiple of revenue) is 1.02x. The EV metrics on screen are based on Q1 financials and come out higher. That said, EV multiples do not fit this company well. Market cap includes the value of mark-to-market stakes such as Samsung Electronics and Samsung Life Insurance (about ₩79.2125 trillion as of November 3), which generate no operating profit, inflating EV. Conversely, operating profit includes 100% of biotech profit, but the outside shareholders' portion of it (a market value of about ₩42.6004 trillion as of November 3) is not in EV. Because the two distortions run in opposite directions, EV multiples alone cannot say whether the stock is cheap or expensive. Free cash flow (FCF, cash from operations minus capital spending) over the last four quarters was about ₩2.7365 trillion, roughly 5.5% of market cap. It includes the biotech outside shareholders' portion, but it is useful as a supplementary gauge of dividend capacity. In Q3 alone, however, working capital (money tied up in operations, such as receivables and inventory) rose by ₩1.204 trillion, leaving operating cash flow at -₩149.0 billion. Shareholder returns are linked to affiliate dividends. The company has said that for 2026-2028 it will return 60-70% of dividends received from affiliates to shareholders, with a minimum of ₩2,500 per share. The 2025 dividend per share was ₩2,800, for a dividend yield of 1.0% at the current price. The Samsung Electronics Q3 dividend (about ₩1.3749 trillion pre-tax for Samsung C&T's share) will enlarge this year's dividend resources, but the actual dividend will not be set until the board decides.

🚀Growth

Over five years, profit has been steadier than revenue. Revenue rose from ₩34.4552 trillion in 2021 to ₩43.1617 trillion in 2022, then fluctuated in the ₩40-42 trillion range, reaching ₩40.7422 trillion in 2025. Operating profit, by contrast, rose four years in a row: ₩1.196 trillion in 2021, ₩2.5285 trillion in 2022, ₩2.8702 trillion in 2023, ₩2.9834 trillion in 2024 and ₩3.2927 trillion in 2025. Net profit attributable to owners also grew from ₩1.635 trillion to ₩2.4391 trillion over the same period. In 2025 alone, revenue fell 3.2%, but operating profit rose 10.4% and attributable net profit 9.4%. In 2026, revenue and operating profit are rising together. Against the same quarter a year earlier, Q1 revenue was +7.5% and operating profit -0.6%, Q2 revenue +19.7% and operating profit +37.1%, and Q3 revenue +18.3% and operating profit +15.0%. For Q1-Q3, revenue was ₩34.4689 trillion (+15.2%), operating profit ₩2.8949 trillion (+17.2%) and attributable net profit ₩1.9977 trillion (+20.9%). Fashion peaks in autumn and winter, leisure in spring and autumn, and trading demand eases at year-end, so comparisons are with the same quarter a year earlier rather than the preceding quarter. Construction led Q3 growth. About half of construction revenue of ₩4.465 trillion came from high-tech work such as chip plants, and operating profit was ₩277.0 billion (a 6.2% margin). Biotech posted the largest operating profit at ₩662.0 billion, but Samsung Biologics' margin fell to 47.3% from 54.0% a year earlier due to the early stage of new plant operations. In trading, urea prices fell from $668 per ton in Q2 to $406 in Q3 and there were no gains from solar asset disposals, so operating profit dropped to ₩99.0 billion from ₩142.0 billion in Q2. Food rose to ₩63.0 billion from ₩53.0 billion a year earlier, and fashion to ₩20.0 billion from ₩12.0 billion. Net profit moved the other way. Other losses of -₩114.0 billion and financial losses of -₩35.0 billion combined to cut Q3 attributable net profit 1.5% year on year to ₩558.0 billion. The volume of work that will become future revenue has grown. The construction order backlog was ₩37.743 trillion at end-September, and Q1-Q3 orders were ₩19.275 trillion. High-tech orders reached ₩11.2 trillion cumulatively, exceeding the company's early-year expectation (₩6.8 trillion), and the company expects ₩12 trillion or more for the full year. On October 28, the company raised its new-order guidance for the year from ₩23.5 trillion to ₩30.1 trillion and kept its revenue guidance at ₩44.5 trillion. With Q1-Q3 revenue alone at ₩34.4689 trillion, the company expects to beat its guidance for both annual revenue and orders. Because the company does not provide profit guidance, this year's profit was calculated in-house by stacking a Q4 estimate on the confirmed quarters. Q4 operating profit is estimated at about ₩1.062 trillion. The company said construction will grow further from Q3 with the start of work on Taylor FAB2 in the US and the ramp-up of data center projects in Malaysia and Yongin, and that fashion and food will also grow. Conversely, it said trading will decline on slowing year-end demand and leisure on park facility renewal costs, while biotech was aligned with the 20% annual revenue growth that Samsung Biologics has guided. Stacked this way, this year's operating profit comes to about ₩3.9569 trillion, up 20.2% from last year. A large non-operating gain is added to net profit. Samsung C&T's share of the Q3 dividend Samsung Electronics approved on October 29 (₩4,601 per share) is about ₩1.3749 trillion pre-tax, and given the resolution timing it is expected to be booked as dividend income in Q4. As a result, this year's attributable net profit is calculated at about ₩3.6141 trillion and the forward P/E at 12.78x. If this special dividend is replaced with a normal quarterly dividend (₩374 per share), net profit would be about ₩2.5942 trillion and the multiple about 19.3x. Next year's earnings rest on high-tech construction, and the company expects high-tech revenue in 2027 to rise substantially from this year.

📰Recent news & filings

Recent disclosures fall into three strands. First, results and the order outlook both improved. Preliminary Q3 results released on October 28 showed revenue of ₩12.008 trillion (+18.3%) and operating profit of ₩1.1428 trillion (+15.0%). The same day, the company raised its new-order guidance for the year from ₩23.5 trillion to ₩30.1 trillion. Construction rights for Seoul redevelopment projects underpin this trend. On August 31, it signed a contract for the Apgujeong District 4 reconstruction (₩2.1154 trillion); in September it was selected as builder for Seongsu Strategic Redevelopment Zone 3 (an expected value of about ₩1.8275 trillion), and in October for the Yeouido Sibum Apartments (an expected value of about ₩2.2685 trillion). The latter two have not yet reached final contracts, so their amounts may change. Group work also increased. On August 31, the finishing work for Phase 2 of Pyeongtaek P4 was raised from ₩1.3792 trillion to ₩1.6997 trillion. On October 20, the company received a letter of award for an overseas project worth at least 2.5% of recent revenue, but details were withheld at the client's request. Second, a large dividend is coming in from an affiliate. On October 29, Samsung Electronics set its Q3 dividend at ₩4,601 per share (versus ₩372 and ₩374 in Q1 and Q2). Samsung C&T's share is about ₩1.3749 trillion pre-tax, payable on November 27. The company has said it will also handle this special dividend under its shareholder return policy. Third, the biotech subsidiary's overseas acquisition is in its final stage. Samsung Biologics is acquiring PolyPeptide, a Swiss contract manufacturer of peptides (short chains of amino acids used as ingredients in obesity and diabetes drugs, among others), through a tender offer (publicly offering to acquire shares from shareholders). On November 6, final acceptances reached 97.98%, above the minimum condition (two-thirds). The acquisition cost on a 100% basis is ₩2.7062 trillion, and the scheduled acquisition date was pushed back a month to December 31. The purchase price is being funded through a rights offering: 2.27 million new shares at a final issue price of ₩1,174,000, raising ₩2.665 trillion. Samsung C&T decided to subscribe for its allotment of 782,818 shares (₩919.0 billion) on November 10. According to the filing, the company being acquired posted revenue of ₩669.2 billion and a net loss of ₩36.1 billion, so it may weigh on biotech margins in the early period after consolidation. At overseas sites, settlement and uncertainty coexist. The Dhaka airport expansion in Bangladesh reached final settlement on October 21, fixing the contract value at ₩2.1639 trillion, up from ₩1.9197 trillion. By contrast, for the UAE high-voltage direct current subsea transmission project (the company's portion ₩2.8764 trillion), the contract end date was removed on October 23 and is under discussion with the client. The construction period for Saeul nuclear units 3 and 4 was extended on September 18 to the end of August 2027. In new businesses, the company signed a joint development agreement for a small modular reactor (SMR) in Sweden in September and invested $70 million in Kairos Power in the US and $200 million in AI infrastructure company Helix, but said it is still too early to talk about related orders or revenue.

🧭Bottom line

Samsung C&T looks cheaper when measured by price relative to its holdings than by earnings multiples. As of November 3, its market cap was 55.0% below the market value of its listed stakes, a wider gap than at SK, HD Hyundai or LG. This year's forward P/E of 12.78x is also on the low side of comparable holding companies' P/Es on confirmed results, so the assessment is undervalued. For that assessment to hold, however, the following conditions need to be watched together. There are four points worth watching. One, investment by Samsung Electronics, the construction division's largest client, is rising. Samsung Electronics disclosed 2026 capital spending of about ₩84.4 trillion, well above ₩52.7 trillion in 2025, and the increased Pyeongtaek P4 contract shows this demand turning into actual work. If the investment is carried out as planned, progress at Pyeongtaek P4 and P5 will rise and construction revenue will follow. Work on Taylor Fab 1 (FAB1) in the US is scheduled for completion on December 31, and the Taylor FAB2 project won in Q3 (₩2.8 trillion) will break ground in Q4 to take its place. Two, affiliate dividends have grown. Memory prices rose across all applications again in Q3, and as long as this boom translates into larger shareholder returns at Samsung Electronics, Samsung C&T's dividend income and shareholder return resources grow with it. Three, biotech demand is solid. Samsung Biologics says Plants 1-4 are running at full capacity and cumulative orders exceed $21.9 billion. US pharmaceutical tariffs (Section 232 of the Trade Expansion Act) are paid by customers importing the drugs, and Korean-made products are capped at 15%. Companies that have both an approved US production plan and a pricing agreement are exempt until January 2029, so the direct impact in Q4 is small. Four, the balance sheet is strong. End-September net cash was ₩4.071 trillion, so participation in the biotech rights offering (₩919.0 billion) can be covered with cash on hand. The points of caution are also clear. One, asset value is tied to Samsung Electronics' share price. As Samsung Electronics' shares fell from ₩334,000 on June 30 to ₩268,500 on September 30, equity attributable to owners dropped by ₩17.406 trillion, and the shares fell further to ₩219,500 by November 3. Output from new memory plants being built by Samsung Electronics, SK Hynix and Micron will arrive in earnest from 2027. Micron's annual filing cites investment by China's CXMT and YMTC as an oversupply risk. If new supply from Korea, the US and China overlaps from the second half of 2027 and memory price gains slow, that would flow through Samsung Electronics' dividends and share price to shrink both this company's dividend income and its asset value. In August, Nvidia announced volume production of an inference accelerator built without high-bandwidth memory (HBM); whether technologies like this that use less memory for AI workloads spread widely is a variable on the same path. Two, this year's forward multiple includes the special dividend effect. At a normal dividend level, the multiple would be about 19.3x, so if dividends at this level do not continue, the multiple on next year's earnings could rise again. Three, there are competitive and substitution risks on the biotech side. Fujifilm pulled forward its North Carolina plant expansion to the end of fiscal 2027, and WuXi Biologics is building a 120,000-liter facility in Singapore (planned for 2029). When this capacity comes online in 2027-2029, competition on terms for large new contracts will intensify. Eli Lilly broke ground on October 22 on a $5 billion in-house plant in Virginia, and an oral small-molecule obesity drug has also been approved. If these trends grow, demand growth for contract manufacturing and peptide ingredients could slow (about 68% of H1 revenue at PolyPeptide, the company being acquired, came from treatments for metabolic diseases such as obesity and diabetes). Four, exchange rates and interest rates are headwinds. The won/dollar rate fell from an H1 average of ₩1,481.78 to ₩1,324.30 on October 28 (the base rate cited in a filing). With 69% of H1 revenue from exports (97% in trading, 96% in biotech), a continued strong won would weigh on revenue and margins once converted into won. The Bank of Korea held its base rate at 3.00% on October 22, leaving the door open to further hikes. If rates rise further, redevelopment associations' financing and construction start dates could be delayed. Five, overseas site risks. At end-June, the remaining value of its Qatar projects was about ₩6.3 trillion, about 18% of the construction backlog, and the end date of the UAE transmission project is under negotiation. If tensions in the Strait of Hormuz flare again, materials transport and construction schedules could be disrupted and costs could rise, and whether those added costs are reimbursed will determine margins. In sum, as long as Samsung Electronics' investment and dividends continue and biotech utilization holds, the current price, far below the value of its holdings, is a strength. Conversely, if memory prices turn down and Samsung Electronics' share price and dividends fall together, or if a strong won and added competing capacity squeeze biotech margins, asset value and earnings could weaken together. Holding company discounts tend to persist for a long time, so narrowing the gap would take a catalyst such as larger shareholder returns.

🔎 Valuation vs peers Undervalued

Large domestic holding companies whose enterprise value centers on stakes in listed affiliates and that either run businesses directly (operating holding companies) or trade at a holding company discount, namely SK (an operating holding company with an IT services business and a large listed portfolio), HD Hyundai (an operating holding company), LG (the benchmark pure holding company) and Hanwha (the closest in structure, running construction and trading businesses within the parent), with P/E, P/B and ROE based on confirmed results calculated by the site at November 3, 2026 closing prices, discounts to holdings value taken from each company page's same-method calculation (SK 38.2%, HD Hyundai 31.6%, LG 19.0%, Hanwha 72.5%, and 53.0% for Samsung C&T on the same method or 55.0% on the detailed recalculation including Samsung Epis Holdings), and the holding company sector medians (P/E 7.36x, P/B 0.47x, forward P/E 4.74x from 21 companies) used only as a reference because many holding companies include one-off gains.

PeerP/EP/BROE
SK Inc.22.69x1.23x26.75%
HD Hyundai10.13x0.89x20.21%
LG Corp.18.60x0.45x1.69%
Hanwha Corporation14.56x0.33x5.74%

The verdict is undervalued, on three grounds. First, price relative to holdings, the first thing to look at for a holding company. At November 3 closing prices, the market value of its listed stakes is ₩111.4275 trillion while its market cap is ₩50.1909 trillion, 55.0% below the value of the stakes. The site's same-method figures are 38.2% for SK, 31.6% for HD Hyundai and 19.0% for LG, so Samsung C&T's gap is wider, though narrower than Hanwha's (72.5%). Subtracting net cash of ₩4.071 trillion and the market value of listed stakes from market cap gives -₩65.3076 trillion, which means the value of the core construction, trading, fashion, leisure and food businesses (this year's operating profit estimated in-house at about ₩1.6519 trillion) is effectively not in the share price. Second, earnings multiples are also on the low side. This year's forward P/E of 12.78x is at the lower end of comparable holding companies' P/Es on confirmed results (SK 22.96x, LG 19.81x, Hanwha 17.7x, HD Hyundai 11.54x). The P/B on September 30 equity attributable to owners is 0.57x, lower than SK (1.24x) and HD Hyundai (1.02x) and higher than LG (0.48x) and Hanwha (0.40x). Third, the confirmed-results metrics on screen are out of date. The screen P/E is based on full-year 2025 earnings and the screen P/B on Q1 equity. Recalculated with the last four quarters of earnings, the P/E is 18.92x, and with September 30 equity, the P/B is 0.74x. There are reasons for the discount too. Mark-to-market stakes such as Samsung Electronics and Samsung Life Insurance contribute earnings only through dividends, and valuation gains are taxed when sold (about ₩18.9592 trillion assuming a 27.5% tax rate; net of tax, the gap is about 45.7%). About 57% of biotech profit belongs to outside shareholders, and asset value is tied to Samsung Electronics' share price (₩334,000 at end-June to ₩219,500 on November 3). On the other hand, the policy of returning 60-70% of affiliate dividends (minimum ₩2,500 per share), the inflow of the Samsung Electronics Q3 dividend, net cash of ₩4.071 trillion, the higher ₩30.1 trillion new-order guidance and Samsung Biologics' 20% revenue growth guidance are factors that could narrow the gap. This year's forward multiple was calculated by adding Q4 segment estimates and the officially disclosed Samsung Electronics dividend to Q1-Q3 results. Replacing this special dividend with a normal level would raise the multiple to about 19.3x, so part of the appeal on the earnings-multiple side is one-off. Even so, the discount to holdings, which is assessed independently of earnings, remains wider than at comparable holding companies, so the verdict stays undervalued. That said, holding company discounts can persist for a long time, and asset value moves with affiliate share prices, which should be kept in view as well.

Price history Close · MA20 · MA60

Close MA20MA60

The latest close is ₩284,500 and the market capitalization is ₩46.1 trillion. The price sits below its 20-day moving average (₩294,050) and below its 60-day moving average (₩335,558). It is under both its short- and medium-term moving averages, so the trend looks subdued. The RSI (a supplementary indicator that gauges the strength of gains versus losses over the past 14 days on a 0-100 scale) is 41.3, a neutral level. The one-month change is -2.4%, the three-month change is -15.3%, and the position relative to the 52-week high is -46.8%. Relative strength versus the KOSPI is 41 (on a 1-99 scale, converted from returns against the index over the past year with more weight on recent performance; higher means stronger than the market). It is stronger than roughly 41% of all stocks. Over the past three months it lagged the index by 2.5%. Chart interpretation is best done alongside trading volume and the dates on which disclosures occur.

Relative performance stock vs index · start = 100

41Relative strength vs KOSPI1–99 · last 12 months’ return vs the index, recency-weighted · higher = stronger than the marketTop 59% strength

Excess return vs index · 3M -2.51% / 6M -7.01% / 12M -1.79%

StockKOSPI

Key metrics Computed vs sector median

Valuation

P/E (trailing)18.92x
Forward P/E12.78x
P/B0.74x
Forward P/B0.71x
P/S1.12x
EPS₩15,041
BPS (book value/share)₩384,083
Dividend yield0.98%
DPS₩2,800

The P/E of 18.92x is above the sector median (7.46x). The P/B of 0.74x is above the sector median (0.45x).

Enterprise value (EV)

Net debt-$648.8M
EV (enterprise value)$33.9B
EV/EBIT13.77x
EV/EBITDA10.42x
EV/Sales1.09x
FCF (free cash flow)$838.2M
FCF yield2.42%

EV = market cap + net debt. It reflects cash and debt, so it captures the real cost of the whole business that market cap alone misses; lower multiples are cheaper relative to earnings or sales.

Intrinsic value (DCF estimate) Estimate

Model output — not a price target. This is what the formula returns under the assumptions below, not a view on where the share price should go.

Bear case₩149,100
Base case₩224,700
Bull case₩399,100

DCF (discounted cash flow) estimate — discount rate 8.6%, initial growth 10.0%→terminal 2.0%, 10-yr forecast, free-cash-flow basis, forward earnings power normalized 1.48x. A reference range that shifts materially with assumptions.

Confidence: Low (bull–bear span 111% of the base case) · Most sensitive assumption: discount rate — a 1%p change moves the base case by roughly 10–20% · Financial basis: FY2025 statements

Profitability & financials

ROE4.15%
Operating margin7.93%
Net margin6.24%
Debt ratio56.15%
Payout ratio18.80%

Return on equity (ROE) is 4.2%, in line with the sector average (4.0%). The operating margin is 7.9%. The debt ratio is 56.1%, so the financial structure is stable.

Growth FY2025 · annual report (consolidated)

Item202320242025YoY
Revenue$31.4B$31.6B$30.5B-3.23% ↓ slower
Operating profit$2.2B$2.2B$2.5B+10.37% ↑ faster
Net profit$1.7B$1.7B$1.8B+9.36% ↑ faster
5-year20212022202320242025
Revenue$25.8B$32.4B$31.4B$31.6B$30.5B
Operating profit$896.5M$1.9B$2.2B$2.2B$2.5B
Net profit$1.2B$1.5B$1.7B$1.7B$1.8B
Revenue CAGR4-yr avg 4.28%

Revenue fell 3.2% year over year (2023 ₩41.9 trillion → 2024 ₩42.1 trillion → 2025 ₩40.7 trillion), and the three-year trend is 'mixed'. The rate of decline widened from the prior year. Operating profit rose 10.4% year over year. Profit is growing at an accelerating pace. Over the 5 years on record, revenue compound annual growth (CAGR) is 4.3%. The two-year revenue CAGR is -1.4%. In the most recent quarter (Q1 2026), revenue was 7.5% higher than the same period a year earlier.

Latest quarterly results Source Q1 2026 · vs year-ago

Revenue$7.8B
Revenue YoY+7.49%
Operating profit$540.0M
Op. profit YoY-0.56%
Net profit$813.9M
Net profit YoY+15.86%

Technical indicators Computed

RSI (14)41.3
MA20₩294,050
MA60₩335,558
1-month-2.40%
3-month-15.33%
vs 52-wk high-46.82%

What stands out

  • P/E and P/B are both low versus peers, so the price looks inexpensive relative to earnings and assets.
  • The balance sheet is stable in terms of debt and liquidity.

Points to watch

  • Revenue fell 3.2% year over year (3-year trend: mixed).

Recent news & events searched · sourced

Figure cross-check computed ↔ external

MetricComputedExternalStatusSource
Sweep of the latest disclosures (as of today)fetch_disclosures days=200 2026-11-06, base 45 major 17 . 3 2026-11-06dart.fss.or.krConfirmedlink
Q3 2026 results checked against the original filingrevenue 12,008,035 / operating profit 1,142,811 / 1,021,289 / net profit 800,865 / net profit 558,048 ; 1~3 34,468,914 / 2,894,911 / 3,443,610 / 2,802,279 / 1,997,732IR 3 p.3: 12,008 / 1,143 / 1,021 / 801 / 558, 34,469 / 2,895 / 3,444 / 2,802 / 1,998; −114· −35· +27Confirmedlink
Quarter-stacked operating profit (2026)Q1 7,204+Q2 1317+Q3 11,428+Q4 1620=3₩956.9 billion(+20.2%)IR 4 · 2025 4 operating profitUnverifiedlink
Quarter-stacked forward P/E (net profit attributable to owners)Q1 8,442+Q2 5,955+Q3 5,580+Q4 16,164=3₩614.1 billion → 50₩190.9 billion ÷ 3₩614.1 billion = 13.9xbase PER 14.96xUnverifiedlink
Samsung Electronics Q3 dividend received and quarter of recognition₩4,601 × 298,818,100 = ₩1,374,862,078,100 → 4 , approx. 1₩110.2 billion21: 2 3 112,954· 542,958 , 2025 3 3 111,763 —Confirmedlink
Key sub-sector metric (discount to NAV)111₩427.5 billion vs 50₩190.9 billion → 55.0%; 56.5%; approx. 45.7%base sector_valuation metric_value 53.0%Mismatchlink
Cash capacity (net cash, FCF yield)9 6₩848.0 billion − 2₩777.0 billion = 4₩71.0 billion; TTM FCF ≈ 4₩17.8 billion − · 1₩281.4 billion = approx. 2₩736.5 billion → approx. 5.5%base enterprise net_debt −₩865.6 billion·FCF 1₩118.2 billion·FCF 2.2%Confirmedlink
P/B (denominator updated)9 88₩147.0 billion ÷ 162,167,581 = ₩543,555 → ₩309,500 0.57xbase PBR 0.81xMismatchlink
P/E (TTM)2025Q4 7,872+2026Q1 8,442+Q2 5,955+Q3 5,580 = net profit 2₩784.9 billion → 18.0xbase PER 20.58xMismatchlink
ROE, debt ratio, current ratio and margins (recalculated at quarter-end and TTM)ROE 3.2% / 9 30 50.2%, 46% / 148.8% / operating margin 8.2%(TTM) / net margin 6.1%base ROE 4.2%· 56.2%· 150.7%·operating margin 7.9%·net margin 6.2%Mismatchlink
The 'negative growth' call in the base diagnostics and summary2026 1~3 revenue 34₩468.9 billion(+15.2%)·operating profit 2₩894.9 billion(+17.2%)·net profit 1₩997.7 billion(+20.9%)base diagnostics growth '', brief ' ', quarter 2026 1Mismatchlink
Audit flag reviewaudit passed, flags 0—Confirmedlink
2026 revenue estimate vs. the company's official guidance1~3 34₩468.9 billion + 4 approx. 11₩932.0 billion = approx. 46₩400.9 billionrevenue ₩44.5 trillion· ₩30.1 trillion, IR ' revenue/ 'Unverifiedlink
Enterprise value (EV) recalculated50₩190.9 billion − 4₩71.0 billion = EV approx. 46₩119.9 billion; EV/EBIT TTM 12.4x·2026e 11.7x; EV/Sales TTM 1.02xbase EV 49₩325.3 billion·EV/EBIT 15.0x·EV/Sales 1.19x·EV/EBITDA 11.35xMismatchlink

Recent filings Source

📖 Plain-language glossary — expand if you are new to this
P/E
How many times a year's net profit the price is worth (lower is cheaper relative to earnings). The P/E here is on trailing (last full-year) results; for companies whose earnings swing fast (memory chips and other cyclicals/high-growth), a forward P/E on this year's expected earnings is more accurate.
P/B
Price relative to net assets (equity). Around 1x means it trades near book value; below 1x means below book.
P/S
Price relative to a year's revenue — useful for growth companies with thin earnings.
Net debt / EV
Net debt = interest-bearing debt − cash. Negative means more cash than debt (net cash). EV (enterprise value) = market cap + net debt, closer to what it would cost to buy the whole business.
EV/EBIT · EV/EBITDA · EV/Sales
Enterprise value against operating profit (EBIT), EBITDA, or revenue. Unlike P/E these reflect debt and cash; lower is cheaper relative to earnings power or sales.
FCF / FCF yield
Free cash flow = operating cash − capex, the cash actually left over. FCF yield = FCF ÷ market cap; higher means more cash generated per unit of market value.
Intrinsic value (DCF)
Future free cash flow (or, for some capex-heavy but profitable names, forecast earnings) discounted to today to estimate per-share value. Because it shifts a lot with the discount-rate and growth assumptions, it is shown as a bear/base/bull range, and the basis and assumptions are disclosed in one line beneath it.
ROE
How much profit the company earns in a year on its equity (%). Higher means better returns on capital.
EPS / BPS
Earnings per share / net assets (book value) per share.
Operating / net margin
Profit left from the core business / final profit after tax and interest, per unit of revenue.
Debt ratio
Debt relative to equity (%). Higher means more reliance on borrowing (norms vary by sector).
Current ratio
Assets convertible to cash within a year against debt due within a year. Above 100% leaves some short-term headroom.
Interest coverage
How many times operating profit covers the interest owed. Below 1x means operating profit alone struggles to cover interest.
Dividend yield / payout ratio
The year's dividend as a % of today's price / the share of earnings paid out as dividends.
Revenue CAGR
Multi-year growth expressed as a single yearly average (compound annual growth rate).
RSI (short-term signal)
Whether recent price action is overheated or beaten down. Above 70 is overbought, below 30 oversold.
MA20 / MA60 (moving averages)
The 20- and 60-day average price. Price above them signals a firmer short-term trend.
vs 52-week high
How far below the past year's peak the price sits now (%).

All figures are for reference only; how they read varies by sector and over time.

Sources: Korea FSC market-price API (data.go.kr), OpenDART, KRX/KIND — public data only.

Bong Stocks presents public-data-based information for reference only. It is not investment advice and contains no target prices, ratings, or buy/sell recommendations. Verify independently before making any decision.